Ссылки
1. Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.
2. Moynihan R., Cassels A. Selling Sickness: how the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005.
3. Weingart S. N., Wilson R. M., Gibberd R. W., et al. Epidemiology of medical error. BMJ. 2000; 320: 774–7.
4. Starfield B. Is US health really the best in the world? JAMA. 2000; 284: 483–5.
5. Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279: 1200–5.
6. Ebbesen J., Buajordet I., Erikssen J., et al. Drug-related deaths in a department of internal medicine. Arch Intern Med. 2001; 161: 2317–23.
7. Archibald K., Coleman R., Foster C. Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines. Lancet. 2011; 377: 1915.
8. Centers for Disease Control and Prevention. Leading Causes of Death. Available online at: www.cdc.gov/nchs/fastats/lcod.htm (accessed 5 February 2013).
9. Lenzer J. Anticoagulants cause the most serious adverse events, finds US analysis. BMJ. 2012; 344: e3989.
10. Centers for Disease Control and Prevention. Tobacco-Related Mortality. Available online at: www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_related_mortality/ (accessed 2 February 2013).
11. Iyer S., Naganathan V., McLachlan A. J., et al. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008; 25: 1021–31.
12. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
13. Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy. 2007 July: 991–1012.
14. Kassirer J. P. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
15. Smith R. The Trouble with Medical Journals. London: Royal Society of Medicine; 2006.
16. Brownlee S. Overtreated: why too much medicine is making us sicker and poorer. New York: Bloomsbury; 2007.
17. World Health Organization. World Health Report 2003 – shaping the future. 2003. Available online at: www.who.int/whr/2003/annex_4_en.xls (accessed 20 December 2012).
18. Reinhardt U. E., Hussey P. S., Anderson G. F. U. S. health care spending in an international context. Health Aff (Millwood). 2004; 23: 10–25.
19. Roehr B. Health care in US ranks lowest among developed countries, Commonwealth Fund study shows. BMJ. 2008; 337: a889.
20. Starfield B., Shi L., Grover A., et al. The effects of specialist supply on populations’ health: assessing the evidence. Health Aff (Millwood). 2001 March 15. DOI: 10.1377/hlthaff.w5.97.
21. World Health Organization. The World Medicines Situation. Available online at: http://apps.who.int/medicinedocs/en/d/Js6160e/6.html#Js6160e6. (accessed 6 February 2013).
22. Wealth but not health in the USA. Lancet. 2013; 381: 177.
23. Nolte E., McKee C. M. Measuring the health of nations: updating an earlier analysis. Health Aff (Millwood). 2008; 27: 58–71.
24. Avendano M., Glymour M. M., Banks J., et al. Health disadvantage in US adults aged 50 to 74 years: a comparison of the health of rich and poor Americans with that of Europeans. Am J Public Health. 2009; 99: 540–8.
25. Jachuck S. J., Brierley H., Jachuck S., et al. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract. 1982; 32: 103–5.
26. Krogsbøll L. T., Jørgensen K. J., Grønhøj Larsen C., et al. General health checks for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2012; 10: CD009009.
27. Johnston M. E., Gibson E. S., Terry C. W., et al. Effects of labelling on income, work and social function among hypertensive employees. J Chronic Dis. 1984; 37: 417–23.
28. Butt D. A., Mamdani M., Austin P. C., et al. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012; 172: 1739–44.
29. Abramson J. Overdo$ed America. New York: HarperCollins; 2004.
30. Oliver M. Let’s not turn elderly people into patients. BMJ. 2009; 338: b873.
31. Cacciotti J., Clinton P. Pharm Exec 50: growth from the bottom up. Pharmaceutical Executive. 2012 May 1. Available online at: www.pharmexec.com/pharmexec/Noteworthy/Pharm-Exec-50-Growth-from-the-Bottom-Up/ArticleStandard/Article/detail/773562 (accessed 17 July 2013).
32. Berwick D. M., Hackbarth, A. Eliminating waste in US health care. JAMA. 2012; 307: 1513–16.
33. Liberati A., Magrini N. Information from drug companies and opinion leaders. BMJ. 2003; 326: 1156–7.
34. Tanne J. H. US healthcare executives hit pay jackpot. BMJ. 2011; 343: d8330.
35. Whelton R. S. Effects of Excessive CEO Pay on U. S. Society. Available online at: www.svsu.edu/emplibrary/Whelton%20article.pdf (accessed 6 November 2007).
36. Schafer A. Biomedical confl icts of interest: a defence of the sequestration thesis – learning from the cases of Nancy Olivieri and David Healy. J Med Ethics. 2004; 30: 8–24.
37. Relman A. A Second Opinion: rescuing America’s health care. New York: Public Affairs; 2007.
38. Krimsky S. Science in the Private Interest: has the lure of profits corrupted biomedical research? Lanham: Rowman & Littlefield; 2003.
39. Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.
40. Goozner M. The $800 Million Pill: the truth behind the cost of new drugs. Berkeley: University of California Press; 2005.
41. Abraham J. Science, Politics and the Pharmaceutical Industry. London: UCL Press; 1995.
42. Day M. MRC says it will invent, develop, and market its own drugs. BMJ. 2007; 334: 1025.
43. Bloemen S., Hammerstein D. Time for the EU to lead on innovation. Health Action International Europe and Trans Atlantic Consumer Dialogue. 2012 April.
44. Bassand J.-P., Martin J., Rydén L., et al. The need for resources for clinical research: The European Society of Cardiology calls for European, international collaboration. Lancet. 2002; 360: 1866–9.
45. Gøtzsche P. C., Hansen M., Stoltenberg M., et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol. 1996; 25: 194–9.
46. Relman A. S., Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.
47. Gøtzsche P. C. Blinding during data analysis and writing of manuscripts. Controlled Clin Trials. 1996; 17: 285–90.
48. Borst-Eilers E. Assessing hospital technology in the Netherlands: new treatments are paid for only if they are part of an evaluation. BMJ. 1993; 306: 226.
49. Garattini S., Bertele V. How can we regulate medicines better? BMJ. 2007; 335: 803–5.
50. Liberati A., Traversa G., Moja L. P., et al. Feasibility and challenges of independent research on drugs: the Italian Medicines Agency (AIFA) experience. Eur J Clin Invest. 2010; 40: 69–86.
51. Light D. W., Lexchin J. R. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012; 344: e4348.
52. Knowler W. C., Barrett-Connor E., Fowler S. E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393–403.
53. Ioannidis J. P., Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001; 285: 437–43.
54. Savulescu J., Chalmers I., Blunt J. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ. 1996; 313: 1390–3.
55. Goldbeck-Wood S. Denmark takes a lead on research ethics. BMJ. 1998; 316: 1189.
56. Goldacre B. Bad Pharma. London: Fourth Estate; 2012.
57. Lundh A., Krogsbøll L. T., Gøtzsche P. C. Access to data in industry-sponsored trials. Lancet. 2011; 378: 1995–6.
58. Lundh A., Krogsbøll L. T., Gøtzsche P. C. Sponsors’ participation in conduct and reporting of industry trials: a descriptive study. Trials. 2012; 13: 146.
59. Heran B. S., Wong M. M. Y., Heran I. K., et al. Blood pressure lowering effi cacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008; 4: CD003823.
60. Directive 2010/84/EU of the European Parliament and of the Council. 2010 Dec 15.
61. Gøtzsche P. C., Liberati A., Luca P., et al. Beware of surrogate outcome measures. Int J Technol Ass Health Care. 1996; 12: 238–46.
62. Apolone G., Joppi R., Bertele V., et al. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to fi nd a balance between different pressures. Br J Cancer. 2005; 93: 504–9.
63. Garattini S., Bertele V. Effi cacy, safety, and cost of new anticancer drugs. BMJ. 2002; 325: 269–71.
64. Machin D., Stenning S. P., Parmar M. K. B., et al. Thirty years of Medical Research Council randomized trials in solid tumours. Clin Oncol. 1997; 9: 100–14.
65. Soares H. P., Kumar A., Daniels S., et al. Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA. 2005; 293: 970–8.